Winchester, MA, United States of America

Anna Kohlmann

USPTO Granted Patents = 11 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 8.2

ph-index = 4

Forward Citations = 31(Granted Patents)

Location History:

Frankfurt-am-Main, DE (2013)
Winchster, MA (US) (2014)
Cambridge, MA (US) (2021 - 2023)
Winchester, MA (US) (2011 - 2024)

Company Filing History:

8 out of 69

Ariad Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Years Active: 2011-2024

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

2. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

3. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

4. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

5. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

6. 9834521 - Choline kinase inhibitors (2017-12-05),

7. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

8. 9273077 - Phosphorus derivatives as kinase inhibitors (2016-03-01),

9. 8912330 - Azaindole derivatives as kinase inhibitors (2014-12-16),

10. 8609681 - Spirocyclic nitriles as protease inhibitors (2013-12-17),

11. 8039480 - Spirocyclic nitriles as protease inhibitors (2011-10-18),

Title: The Innovative Contributions of Anna Kohlmann

Introduction

Anna Kohlmann is a prominent inventor based in Winchester, MA (US), known for her significant contributions to the field of pharmaceutical sciences. With a total of 11 patents to her name, she has made remarkable strides in developing compounds that target critical pathways in cancer treatment.

Latest Patents

Among her latest patents, Kohlmann has developed heteroaryl compounds for kinase inhibition. These compounds and pharmaceutical compositions are designed to modulate kinase activity, particularly focusing on mutant EGFR and mutant HER2 kinase activity. Additionally, she has created aminothiazole compounds that serve as c-Kit inhibitors, which are useful in treating cancers and other diseases mediated by serine-threonine kinases.

Career Highlights

Throughout her career, Anna Kohlmann has worked with notable companies such as Ariad Pharmaceuticals, Inc. and Sanofi-Aventis. Her work has been instrumental in advancing therapeutic options for patients suffering from various conditions related to kinase activity.

Collaborations

Kohlmann has collaborated with esteemed colleagues, including William C. Shakespeare and Feng Li, further enhancing her research and development efforts in the pharmaceutical industry.

Conclusion

Anna Kohlmann's innovative work in the field of kinase inhibition and cancer treatment exemplifies her dedication to advancing medical science. Her contributions continue to impact the development of effective therapies for challenging diseases.

This text is generated by artificial intelligence and may not be accurate.